Uscom Limited (UCM) AI Stock Analysis

• Market Cap: AU$3.12M
• Dividend Yield: N/A
• Average Volume (3M): 3.23K
• Price to Earnings (P/E): ―
• Beta (1Y): -1.59
• Revenue Growth: -30.80%
• EPS Growth: -38.95%
• Country: AU
• Employees: 35
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Devices
• EPS (TTM): >-0.01
• Shares Outstanding: 260,147,130
• 10 Day Avg. Volume: 0
• 30 Day Avg. Volume: 3,233
• PEG Ratio: -0.02
• Price to Book (P/B): -76.24
• Price to Sales (P/S): 1.13
• P/FCF Ratio: -1.07
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: Moderate Sell
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 39 Underperform
• Price Target: AU$0.00 ▼(-100.00% Downside)

Uscom Limited's overall stock score is primarily impacted by its weak financial performance and unfavorable valuation metrics. The company's financial instability, characterized by declining revenues and negative equity, is a significant concern. Additionally, technical analysis indicates bearish momentum, further contributing to the low score. The absence of earnings call data and corporate events means these factors do not influence the score.

Uscom Limited Business Overview & Revenue Model

Company Description

Uscom Limited (UCM) is a publicly traded medical technology company based in Australia, specializing in the development and commercialization of innovative non-invasive monitoring devices. The company operates primarily in the healthcare sector, focusing on products that provide real-time hemodynamic monitoring. Uscom's core offerings include the Uscom 1A, a device used for measuring cardiac output and other vital parameters, aimed at improving patient outcomes in various clinical settings.

How the Company Makes Money

Uscom generates revenue through the sale of its medical devices, primarily the Uscom 1A, to hospitals, clinics, and healthcare providers. The company also benefits from recurring revenue generated through service contracts, maintenance agreements, and training for healthcare professionals. Additionally, Uscom may engage in partnerships and collaborations with other medical technology firms and healthcare organizations to enhance its product offerings and expand its market reach, contributing to its overall earnings.

Uscom Limited Financial Statement Overview

Summary

Uscom Limited is facing significant financial challenges. The income statement shows a substantial decline in revenue and ongoing losses, with negative net profit and EBIT margins. The balance sheet reveals financial instability with negative stockholders' equity and a highly unfavorable debt-to-equity ratio. Although there is some improvement in free cash flow, overall financial health is concerning due to high leverage and insufficient profitability.

Income Statement

Uscom Limited's income statement reveals significant challenges. The company has experienced a substantial decline in revenue, with a negative revenue growth rate of -28.98% in the most recent year. Profitability metrics are concerning, with negative net profit and EBIT margins, indicating ongoing losses. The gross profit margin remains high at 86.48%, suggesting some operational efficiency, but overall financial performance is weak due to persistent losses.

Balance Sheet

The balance sheet of Uscom Limited shows financial instability. The company has a negative stockholders' equity, leading to a highly unfavorable debt-to-equity ratio of -59.22. This indicates potential solvency issues. Return on equity is alarmingly high at 86.41%, driven by negative equity, which is not sustainable. The equity ratio is also negative, reflecting a precarious financial position.

Cash Flow

Cash flow analysis for Uscom Limited indicates some improvement in free cash flow growth, which is positive at 79.47%. However, operating cash flow remains negative, and the operating cash flow to net income ratio is below 1, suggesting insufficient cash generation to cover losses. The free cash flow to net income ratio is slightly above 1, indicating some ability to manage cash flow despite ongoing losses.

Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	2.58M	2.58M	3.73M	2.66M	2.51M	3.86M
Gross Profit	2.23M	2.23M	3.12M	-1.03M	-1.21M	781.70K
EBITDA	-3.06M	-3.06M	-1.51M	-2.50M	-1.84M	-833.84K
Net Income	-3.30M	-3.30M	-2.07M	-2.59M	-1.97M	-924.24K
Balance Sheet
Total Assets	3.25M	3.25M	5.13M	5.18M	7.99M	5.33M
Cash, Cash Equivalents and Short-Term Investments	966.66K	966.66K	2.52M	2.18M	4.70M	1.71M
Total Debt	2.26M	2.26M	989.28K	1.09M	1.31M	1.43M
Total Liabilities	3.29M	3.29M	2.07M	2.14M	2.06M	2.26M
Stockholders Equity	-38.22K	-38.22K	3.06M	3.04M	5.94M	3.08M
Cash Flow
Free Cash Flow	-2.72M	-2.72M	-1.22M	-1.58M	-1.08M	21.63K
Operating Cash Flow	-2.71M	-2.71M	-1.16M	-1.42M	-967.51K	54.98K
Investing Cash Flow	-68.78K	-68.78K	-57.55K	-151.94K	-115.31K	-33.35K
Financing Cash Flow	1.21M	1.21M	1.57M	-952.96K	4.05M	-281.87K

Uscom Limited Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 0.01
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Positive
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:UCM, the sentiment is Negative. The current price of 0.01 is below the 20-day moving average (MA) of 0.01, below the 50-day MA of 0.01, and below the 200-day MA of 0.02, indicating a bearish trend. The MACD of >-0.01 indicates Negative momentum. The RSI at 9.09 is Positive, neither overbought nor oversold. The STOCH value of -66.67 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for AU:UCM.

Uscom Limited Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
HMD	45 Neutral	€36.47M	-6.73	-513.22%	―	-34.06%	75.47%
CBL	45 Neutral	AU$13.43M	-1.63	-103.74%	―	14.84%	39.64%
AT1	43 Neutral	AU$21.87M	-3.51	-58.27%	―	-7.20%	28.70%
UCM	39 Underperform	AU$3.12M	-0.91	-218.52%	―	-30.80%	-38.95%
IRX	38 Underperform	AU$5.67M	-4.19	―	―	―	-55.00%
ADR	37 Underperform	AU$8.67M	-0.64	-1476.79%	―	-2.82%	32.47%

Uscom Limited Corporate Events

Uscom Limited Seeks Shareholder Approval for Major Asset Sale

Uscom Limited has announced a General Meeting to seek shareholder approval for the sale of its main undertaking, Uscom Sng Pte. Ltd, to AXO Medtech VCC. This strategic move is driven by Uscom’s ongoing financial challenges, including sustained losses and negative cash flow, which have hindered its ability to raise capital and develop its business. The sale is expected to provide the necessary capital for Uscom’s operations to become profitable, with AXO Medtech VCC intending to continue Uscom’s current business operations, retain employees, and enhance global operations.

Uscom Limited Announces Sale to AXO Medtech VCC

Uscom Limited has announced an agreement to sell its entire business and assets to AXO Medtech VCC, a Singapore-based investment company, subject to shareholder approval. This strategic move aims to address Uscom’s financial difficulties and enable the business to raise necessary capital for transformation into a profitable entity. The sale includes all shares in its subsidiary, UCM SNG, for $2.591 million, which will be settled by transferring existing liabilities. AXO plans to continue Uscom’s operations, retain employees, and raise capital to expedite global expansion. The transaction is expected to be completed by late November 2025, pending shareholder approval.

Uscom Limited Faces Suspension from ASX Quotation

Uscom Limited, a company listed on the Australian Securities Exchange (ASX), has had its securities suspended from quotation due to inadequate financial conditions. The ASX determined that Uscom Limited breached Listing Rule 12.2 after reviewing the company’s annual financial statements and the auditor’s disclaimer of opinion. The suspension will remain in effect until Uscom Limited complies with the ASX’s listing rules and it is deemed appropriate for its securities to be reinstated.

Uscom Limited Releases 2025 Corporate Governance Statement

Uscom Limited has released its Corporate Governance Statement for the financial year ending June 30, 2025, detailing its adherence to the ASX Corporate Governance Council’s Principles and Recommendations. The company emphasizes its commitment to high standards of corporate governance, ethical conduct, and shareholder value creation. The statement outlines the roles and responsibilities of the Board and senior management, highlighting the absence of a formal diversity policy due to the company’s size and development stage. Uscom plans to establish a skills matrix and formal evaluation processes in the next reporting period, reflecting its ongoing efforts to enhance governance practices.

Uscom Limited Releases 2025 Corporate Governance Statement

Uscom Limited has released its Corporate Governance Statement for the financial year ending June 30, 2025, which is available on their website. The statement confirms the company’s adherence to the ASX Corporate Governance Council’s principles and recommendations, highlighting their commitment to transparency and accountability in management and oversight. This disclosure is expected to reinforce stakeholder confidence and support Uscom’s strategic positioning in the medical technology sector.

Uscom Limited Reports Decline in Revenue and Increased Losses for FY2025

Uscom Limited reported a 25% decline in revenues from ordinary activities to $3,158,359 for the financial year ending June 30, 2025. The company also experienced a 59% increase in net loss, amounting to $3,302,759, and announced that no dividends will be paid. These financial results indicate significant challenges for Uscom, impacting its market positioning and raising concerns for stakeholders about the company’s financial health and future strategies.

Uscom Limited Navigates Market Challenges with Strategic Focus

Uscom Limited reported a challenging Q4 2025 with a decrease in customer receipts and cash on hand compared to previous periods, attributed to global market instability. Despite these challenges, Uscom is focusing on cost control, expanding sales and distribution partnerships, and developing growth strategies for a market rebound. The company continues product development, with its BP+ technology gaining recognition and regulatory approval for its SpiroSonic devices in China, positioning Uscom for future growth in the global medical device market.